Close Menu

NEW YORK (GenomeWeb) — Norwegian bioinformatics firm OncoImmunity announced on Monday that it has received €2.2 million ($2.5 million) in funding from the European Innovation Council to further develop its ImmuneProfiler personalized cancer medicine platform.

ImmuneProfiler applies machine learning to next-generation sequencing data to predict the immunogenic neoantigens in individual cancer patients that can serve as therapeutic targets and immunotherapy biomarkers, according to OncoImmunity.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.

Jul
31
Sponsored by
Thermo Fisher Scientific

This webinar will provide a first-hand look at how a molecular laboratory validated and implemented a targeted next-generation sequencing-based myeloid assay to expedite the assessment of myeloid malignancies and assist in the understanding of myeloid cancers.

Aug
28
Sponsored by
Horizon Discovery

This webinar will provide an overview of alternatives to the popular Cas9 nuclease used in CRISPR gene editing.